Taysha Gene Therapies, Inc. / Fundamentals
Income statement
- Net revenue
€6.95M - Cost of goods sold
€237.67K - Gross profit
€6.71M - SG&A expenses
€26.84M - R&D expenses
€56.61M - EBITDA
-€78.63M - D&A
€993.56K - EBIT
-€80.66M - Interest expenses
€70.36K - EBT
-€79.55M - Tax expenses
€0.00 - Net income
-€79.55M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€6.17M - Changes in working capital
-€9.28M - Operating cash flow
-€70.46M - Capex
€356.07K - Other investing cash flow
€70.36K - Net investing cash flow
-€284.00K - Total cash dividends paid
€0.00 - Issuance of common stock
€190.88M - Debt repayment
€0.00 - Other financing cash flow
€4.29K - Net financing cash flow
€190.88M - Foreign exchange effects
€0.00 - Net change in cash
€120.14M - Cash at end of period
€270.58M - Free cash flow
-€70.11M
Balance sheet
- Cash and cash equivalents
€268.35M - Cash and short-term investments
€268.35M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.01M - Total current assets
€271.35M - Property, plant & equipment
€12.64M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.85M - Other non-current assets
€159.59K - Total non-current assets
€14.64M - Total assets
€286.00M - Accounts payable
€6.62M - Short-term debt
€1.84M - Other current liabilities
€8.58M - Total current liabilities
€21.75M - Long-term debt
€28.99M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€36.42M - Total non-current liabilities
€50.84M - Total liabilities
€72.59M - Common stock
€2.57K - Retained earnings
-€558.31M - Other equity
-€599.74K - Total equity
€213.41M - Total liabilities and shareholders' equity
€286.00M
Company information
- Market capitalization
€530.91M - Employees
73 - Enterprise Value
€598.79M
Company ratios
- Gross margin
-
96.6% Much better than peer group: -120.0% - EBITDA margin
-
-1,131.7% Much better than peer group: -4,116.2% - EBIT margin
-
-1,160.8% Much better than peer group: -4,413.6% - EBT margin
-
-1,145.0% Much better than peer group: -3,971.8% - Net margin
-
-1,145.0% Much better than peer group: -3,956.6% - ROE
-
-37.3% Even with peer group: -39.1% - ROA
-
-27.8% Better than peer group: -45.0% - Asset turnover
-
2.4% Even with peer group: 4.4% - FCF margin
-
-1,019.3% Much better than peer group: -3,514.4% - FCF yield
-13.3% - Efficiency ratio
1,231.7% - Net sales per employee
-
€95.18K - Net income per employee
-
-€1.09M